Angiotensin-converting enzyme (ACE) inhibitors, which prevent the conversion of
angiotensin I to angiotensin II, are well-known for the treatments of cardiovascular diseases …

The four major diagnostic criteria for the syndrome of congestive heart failure are left
ventricular dysfunction, exercise intolerance, pulmonary congestion or edema and …

Angiotensin converting enzyme (ACE) inhibitors are a cornerstone of therapy for heart
failure. Large-scale clinical trials show that ACE inhibitors reduce morbidity and mortality in …

The development of heart failure under various pathological conditions such as myocardial
infarction (MI), hypertension and diabetes are accompanied by adverse cardiac remodeling …

Heart failure has become the most widely studied syndrome in cardiology over the recent
years. Despite the encouraging achievements by angiotensin converting enzyme (ACE) …

Congestive heart failure (CHF) continues to be a major cause of morbidity and mortality; in
the United States alone, CHF afflicts 4 million patients, representing about 2% of the adult …

Congestive heart failure is the end product of a progressive series of events resulting from
acute myocardial damage. Circulatory neurohormonal systems are activated during the …

Our understanding of the clinical course of heart failure and the mechanism by which ACE
inhibitors reduce mortality and morbidity is being enhanced by recent results from large …

The ideal therapy for patients with chronic heart failure should reduce symptoms related to
pulmonary congestion or low perfusion, prevent the progression of left ventricular …

In recent years, there has been much attention devoted to the endocrine and neurohumoral
responses to myocardial failure, their participation in the pathophysiology of the disorder …